Myeloproliferative Neoplasms

Health-Related Quality of Life in Patients with MPN Versus General Public

A study published in Cancers (Basel) assessed the health-related quality of life in patients with myeloproliferative neoplasms (MPNs) and found that fatigue and sexual...

PARP Inhibitors Associated with Development of MDS and AML

The use of poly (ADP-ribose) polymerase (PARP) inhibitors increased the risk of developing myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) compared with placebo, according to...

Study Identifies Factors Associated with De Novo and Therapy-Related MDS

A study published in Cancer Causes & Control observed that smoking, history of autoimmune disease, and benzene exposure were associated with de novo and...

Depression Common in Patients with Myeloproliferative Neoplasms

About one-quarter of patients with myeloproliferative neoplasms (MPNs) may have significant depression symptoms, according to a study published in Cancer Medicine. This study utilized responses...

DOACs Effective for Prevention of Thromboembolic Events in Patients with MPN

A study published in the Annals of Hematology found that direct oral anticoagulants (DOACs) were effective and safe as vitamin K antagonists (VKAs) for...

Real-World Study Evaluates Survival Gains Before and After Approval of Ruxolitinib for Myelofibrosis

A real-world study presented at the ASH Annual Meeting & Exposition found that one-year overall survival (OS) among patients with intermediate- or high-risk myelofibrosis...

MPN Driver Mutations Can Be Acquired as Early as In Utero

The JAK2V617F mutation is the most common myeloproliferative neoplasm (MPN) phenotypic driver mutation, and a study presented at the ASH Annual Meeting & Exposition...

Journal Reading List

Advertisement
Advertisement
click me